Biofrontera Inc. (BFRI)
$9.2
+0.65 (+7.60%)
Rating:
Recommendation:
-
| Symbol | BFRI |
|---|---|
| Price | $9.2 |
| Beta | 0.000 |
| Volume Avg. | 0.02M |
| Market Cap | 12.582M |
| Shares () | - |
| 52 Week Range | 7.4-25.8 |
| 1y Target Est | - |
| DCF Unlevered | BFRI DCF -> | |
|---|---|---|
| DCF Levered | BFRI LDCF -> | |
| ROE | -128.79% | Strong Sell |
| ROA | -61.42% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 30.60% | Neutral |
| P/E | -0.50 | Neutral |
| P/B | 0 | Neutral |
Latest BFRI news
About
Download (Excel)Dr. Hermann Luebbert Ph.D.
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.